Artificial intelligence to improve 3D cell culture : a milestone for HCS pharma

As you may now, in HCS Pharma we strongly believe that the critical point of the human health evolution in next years is the in vitro 3D cell culture, especially for complex diseases like cancer [1]. It’s why we work hard on our exclusive BIOMIMESYS® technology. As experts in HCS and cell imaging, we must master all the process : 3D biological models, 3D cell culture, volumetric pictures acquisition, 3D reconstruction and segmentation of cells and ECM compounds, 3D parameters extraction and, of course, biological interpretations. As explained in our VisuAI R&D project, the 3D reconstruction and segmentation step is not simple.

BIOMIMESYS® Oncology is a relevant hydroscaffold for cancer-related in vitro studies

BIOMIMESYS® Oncology is mostly composed of hyaluronic acid (HA), biofunctionnalized with undenaturated collagen I. HA, by interacting with its binding proteins (CD44, RHAMM, ICAM-1), is an active participant in inflammatory, angiogenic, fibrotic and cancer-promoting processes (Figure 1). We are currently looking at the effect of different elastic moduli of BIOMIMESYS® Read more…

New Content Screening Platform for Cancer Applications

“A new high-content screening software platform enables cancer researchers to uncover more about basic and advanced cellular function to accelerate cell-based research. The Thermo Scientific HCS Studio 2.0 is a high-content quantitative imaging and analysis software platform for a range of cancer research applications, including angiogenesis and migration/invasion, as well Read more…